Print
Email
Print Edition StoriesWednesday, March 10, 2010
Ischemix moves prevention drug to Phase 2a trials
By Mass High Tech staff
MHT's Jackie Noblett: Maine becoming a hub for pet-oriented biotechs
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Maynard biotechnology firm Ischemix LLC has begun a Phase 2a trial of its cardio-protective drug, CMX-2043.
The drug candidate is intended to prevent peri-operative ischemia-reperfusion injury, a temporary increase in insufficient blood flow, in patients following percutaneous coronary intervention (PCI) procedures that are meant to treat those symptoms.
The Phase 2a trial will test the safety of an injection of CMX-2043 by measuring biomarkers of cardiac damage. The trial will also evaluate the efficacy of the drug candidate as seen through electrocardiographic and cardiac biomarker monitoring.
If approved, CMX-2043 would become the first treatment to protect against ischemia-reperfusion injury, according to Ischemix CEO Robert ‘Duffy’ DuFresne.
Ischemix was established from research conducted at MIT and Harvard University. Dufresne was appointed CEO last year after serving as a member of the board of directors since May 2007.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
